Results 51 to 60 of about 6,034 (173)
HIV-1 subtype C predicted co-receptor tropism in Africa: an individual sequence level meta-analysis
AIDS Research and Therapy, 2020 Background Entry inhibitors, such as Maraviroc, hold promise as components of HIV treatment and/or pre-exposure prophylaxis in Africa. Maraviroc inhibits the interaction between HIV Envelope gp120 V3-loop and CCR5 coreceptor. HIV-1 subtype C (HIV-1-C) is
Nontokozo D. Matume +2 more
doaj +1 more source
Recent Developments in HIV Antivirals: The Prospect of Prophylactic Drugs to Change the Pandemic
Microbial Biotechnology, Volume 19, Issue 2, February 2026.Replication cycle of HIV‐1. The scheme provides an overview from virus entry over reverse transcription of viral RNA into viral DNA, provirus DNA integration into the host genome, genome expression by transcription and translation, proteolytic processing of the viral polyproteins, viral maturation to viral release from the cell. The various targets for
Harald Brüssow
wiley +1 more source
Stromal Cell‐Mast Cell Communication Orchestrates Anti‐Viral Immunity in the Meninges
Advanced Science, Volume 13, Issue 5, 27 January 2026.This study delineates the spatial distribution and postnatal maturation of meningeal mast cells and uncovers their essential role in antiviral immunity. Using genetic models, mast cells are shown to promote CD8⁺ T cell infiltration and viral clearance via IL‐33 receptor signaling and synergistic activation by IL‐33 and ATP from infected stromal cells ...
Qingqing Li +7 more
wiley +1 more source
VirusesHIV-1 typically infects cells via the CD4 receptor and CCR5 or CXCR4 co-receptors. Maraviroc is a CCR5-specific viral entry inhibitor; knowledge of viral co-receptor specificity is important prior to usage. We developed and validated an economical V3-env
Daisy Ko +7 more
doaj +1 more source
PLoS ONE, 2013 BackgroundDual/mixed-tropic HIV-1 strains are predominant in a significant proportion of patients, though little information is available regarding their replication-capacity and susceptibility against CCR5-antagonists in-vitro.
Matteo Surdo +11 more
doaj +1 more source
Advanced Science, Volume 12, Issue 45, December 4, 2025.Genomic data offer a powerful tool for studying the molecular interactions between parasites and their hosts, but they remain scarce for parasitic monogenean flatworms. This study presents the first high‐quality phased genome assembly for monogeneans (Gyrodactylus kobayashii), and uses it to predict key interacting proteins between monogenean parasite ‐
Dong Zhang +17 more
wiley +1 more source
PLoS ONE, 2013 Maraviroc, an (HIV-1) entry inhibitor, binds to CCR5 and efficiently prevents R5 human immunodeficiency virus type 1 (HIV-1) from using CCR5 as a coreceptor for entry into CD4(+) cells.
Yuzhe Yuan +6 more
doaj +1 more source
Scientific Reports, 2020 Human immunodeficiency virus (HIV) remains incurable due to latent viral reservoirs established in non-activated CD4 T cells that cannot be eliminated via antiretroviral therapy.
María Rosa López-Huertas +9 more
doaj +1 more source
Maraviroc in the treatment of HIV infection
Drug Design, Development and Therapy, 2008 While a successful HIV vaccine will likely take several more years to become a reality, many anti-retroviral (ARV) drugs are currently available to treat HIV infection, and their efficacious use has improved the quality of life and life expectancy of millions of HIV-infected individuals.
openaire +3 more sources
Spatial transcriptomics in epilepsy research: Early successes, opportunities, and challenges
Epilepsia, Volume 67, Issue 4, Page 1589-1600, April 2026.
Donald J. Phillips +4 more
wiley +1 more source